Townsend, Maryland Clinical Trials

A listing of Townsend, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

hras gene
recurrent thyroid gland carcinoma
donor lymphocyte infusion
HRAS
nitrosoureas
Sinai Hospital of Baltimore
 (5.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

schwartz
glioma
neutrophil count
nf2 gene
crizotinib
Johns Hopkins University (Site 250)
 (7.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF

This is a prospective non-blinded randomized control pilot study comparing the effect of pulmonary vein isolation against medical management of atrial fibrillation in patients with Heart Failure with preserved Ejection Fraction (HFpEF).

b-type natriuretic peptide
left ventricular hypertrophy
nt-probnp
cardioversion
fibrillation
Johns Hopkins Hospital
 (7.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow …

bilateral oophorectomy
hematopoietic and lymphoid cell neoplasm
solid tumor
steroid-refractory pneumonitis
hematologic malignancy
Jarushka Naidoo
 (9.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia

Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. There are three different variants of PPA, each a relatively distinct speech and language profile. For individuals with non-fluent variant PPA (nfvPPA), a core symptom is apraxia of speech (AOS), which is defined as an …

language testing
transcranial direct current stimulation
neurodegeneration
aphasia
apraxia of speech
Johns Hopkins Hospital
 (7.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-nave patients with non-muscle invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen. In addition to providing initial …

bilateral oophorectomy
combination therapy
serum pregnancy test
invasive bladder cancer
oophorectomy
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
 (7.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

combination therapy
testosterone
antiandrogens
antiandrogen therapy
taxane
Johns Hopkins University
 (7.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

deficiency
eliglustat
imiglucerase
gaucher disease
Investigational Site Number 840044
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840044
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

myozyme
replacement therapy
glycogen storage disease type ii
gaa gene
deficiency
Investigational Site Number 840044
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations